CA2857490C - Guanine analogs as telomerase substrates and telomere length affectors - Google Patents

Guanine analogs as telomerase substrates and telomere length affectors Download PDF

Info

Publication number
CA2857490C
CA2857490C CA2857490A CA2857490A CA2857490C CA 2857490 C CA2857490 C CA 2857490C CA 2857490 A CA2857490 A CA 2857490A CA 2857490 A CA2857490 A CA 2857490A CA 2857490 C CA2857490 C CA 2857490C
Authority
CA
Canada
Prior art keywords
compound
hydrogen
alkyl
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2857490A
Other languages
English (en)
French (fr)
Other versions
CA2857490A1 (en
Inventor
Sergei M. Gryaznov
Ronald A. Pruzan
Krisztina Pongracz
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CA2857490A1 publication Critical patent/CA2857490A1/en
Application granted granted Critical
Publication of CA2857490C publication Critical patent/CA2857490C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2857490A 2011-12-22 2012-12-21 Guanine analogs as telomerase substrates and telomere length affectors Active CA2857490C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579575P 2011-12-22 2011-12-22
US61/579,575 2011-12-22
PCT/US2012/000586 WO2013095684A1 (en) 2011-12-22 2012-12-21 Guanine analogs as telomerase substrates and telomere length affectors

Publications (2)

Publication Number Publication Date
CA2857490A1 CA2857490A1 (en) 2013-06-27
CA2857490C true CA2857490C (en) 2020-03-31

Family

ID=48669322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2857490A Active CA2857490C (en) 2011-12-22 2012-12-21 Guanine analogs as telomerase substrates and telomere length affectors

Country Status (7)

Country Link
US (5) US9593137B2 (enExample)
EP (2) EP3578563B1 (enExample)
JP (2) JP6113185B2 (enExample)
CA (1) CA2857490C (enExample)
DK (2) DK3578563T3 (enExample)
ES (2) ES2874774T3 (enExample)
WO (1) WO2013095684A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578563B1 (en) * 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PE20181016A1 (es) 2015-08-10 2018-06-26 Merck Sharp & Dohme Compuestos antivirales de fosfodiamida de ester de beta aminoacido
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
KR20250074692A (ko) 2018-11-29 2025-05-27 제론 코포레이션 골수이형성 증후군을 치료하는 방법
CN111205326B (zh) * 2020-02-13 2020-09-22 南京道尔医药科技有限公司 一种绿色环保的泰诺福韦制备方法
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
AU8092587A (en) 1986-11-18 1988-05-19 Bristol-Myers Squibb Company Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
NZ222553A (en) 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
EP0405748A1 (en) 1989-05-30 1991-01-02 Beecham Group p.l.c. Phosphonoderivative of purine with antiviral activity
PT97407B (pt) 1990-04-20 1998-08-31 Rega Stichting Processo para a preparacao de (r)-9-{2-(fosfono-metoxi)-propil}-guanina
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
JP3116079B2 (ja) 1990-08-10 2000-12-11 インスティチュート オブ オーガニック ケミストリ アンド バイオケミストリ アカデミー オブ サイエンス オブ ザ チェコ リパブリック ヌクレオチドの新規な製法
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
GB9020932D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
HU225970B1 (en) 1991-10-11 2008-01-28 Acad Of Science Czech Republic Antiviral acyclic phosphonomethoxyalkyl-substituted alkenyl purine and pyrimidine derivatives, and pharmaceutical preparations containing them
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
IT1270008B (it) 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
JP3906488B2 (ja) 1995-02-21 2007-04-18 味の素株式会社 プリン誘導体の製造方法
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CA2224710A1 (en) 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
CA2195262C (en) 1996-01-18 2005-08-09 Masaru Ubasawa Phosphonate nucleotide compounds
US5874577A (en) 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6194398B1 (en) 1996-08-13 2001-02-27 Mitsubishi Chemical Corporation Phosphonate nucleotide compound
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6252061B1 (en) 1998-03-23 2001-06-26 Reliable Biopharmaceutical, Inc. Process for the production of 2-halo-6-aminopurine derivatives
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
CN1426418A (zh) 2000-02-29 2003-06-25 三菱制药株式会社 膦酸酯核苷酸化合物
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
KR20020097384A (ko) 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
WO2003028737A1 (en) 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
PL374525A1 (en) 2001-11-14 2005-10-31 Biocryst Pharmaceuticals, Inc. Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
US6858393B1 (en) 2002-03-13 2005-02-22 Stratagene California Chain terminators for DNA synthesis
EP1497304B1 (en) 2002-04-12 2014-06-25 Catalyst Assets LLC Dual-labeled nucleotides
EP2223927B1 (en) 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
TW200402299A (en) 2002-05-24 2004-02-16 Mitsubishi Pharma Corp Drugs improved in tissue selectivity
US20040157793A1 (en) 2002-11-12 2004-08-12 Stuyver Lieven J. Modified nucleosides as antiviral agents
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
WO2004106350A1 (en) 2003-05-14 2004-12-09 Biocryst Pharmaceutical, Inc. Nucleoside analogs as viral polymerase inhibitors
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
US20060252729A1 (en) 2003-07-30 2006-11-09 Krawczyk Steven H Nucleobase phosphonate analogs for antiviral treatment
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
ATE478082T1 (de) 2003-12-30 2010-09-15 Gilead Sciences Inc Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8063209B2 (en) 2004-07-02 2011-11-22 Tsrl, Inc. Phosphonyl ester conjugates as prodrugs
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
ITFI20040173A1 (it) 2004-08-03 2004-11-03 Protera S R L Profarmaci attivati da dna polimerasi dipendenti da rna
ES2401285T3 (es) * 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
CN104997783A (zh) 2005-03-25 2015-10-28 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
ES2261072B1 (es) 2005-04-06 2007-12-16 Consejo Superior Investig. Cientificas Fosforotioatos derivados de analogos a nucleosido para terapia antirretroviral.
WO2006114065A2 (en) 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry A Cademy Of Sciences Of The Czech Republic Use of compounds to inhibit neoplasia
JP2008545658A (ja) 2005-05-18 2008-12-18 アルト ソリューションズ インコーポレーテッド 癌の予防及び治療のための、癌細胞におけるテロメア長の薬理学的調節
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007014491A1 (fr) 2005-08-03 2007-02-08 Beijing Fu Kang Ren Bio-Pharm Tech.Co.Ltd. Phosphonates de nucléotides acycliques et leur utilisation dans des agents antiviraux
WO2007106450A2 (en) 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
JP4937279B2 (ja) 2006-06-30 2012-05-23 パナソニック株式会社 ノード発見方法
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
FR2908133B1 (fr) 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
AU2008246195B2 (en) 2007-04-27 2014-06-05 Emergent Biodefence Operations Lansing Llc Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates
WO2008134578A2 (en) 2007-04-28 2008-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Synthesis of optically active radio-labeled reverse transcriptase inhibitors
GB0709408D0 (en) 2007-05-16 2007-06-27 Katholleke Universiteit Leuven Anti-col herpes virus compounds
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009115927A2 (en) 2008-03-18 2009-09-24 Institut De Recherches Cliniques De Montreal Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
WO2009120358A1 (en) 2008-03-27 2009-10-01 Nektar Therapeutics Oligomer-nitrogenous base conjugates
BRPI0910891A2 (pt) 2008-04-15 2015-09-29 Mallinckrodt Inc composições contendo compostos antivirais e métodos de usar os mesmo
JP5798918B2 (ja) 2008-08-21 2015-10-21 ナインポイント メディカル， インコーポレイテッド 薬物評価および局所処置のためのデバイスおよび方法
EP2393815A4 (en) 2009-02-06 2012-11-21 Rfs Pharma Llc PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
WO2011011710A1 (en) 2009-07-24 2011-01-27 Chimerix, Inc. Methods of treating viral infections
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CA2779473C (en) 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
EA201270651A1 (ru) 2009-12-07 2013-01-30 Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
US20130028920A1 (en) 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
EP2558466A4 (en) 2010-04-14 2013-11-13 Univ California PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS
US8940313B2 (en) 2010-04-23 2015-01-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
WO2011159471A2 (en) 2010-06-18 2011-12-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Linked purine pterin hppk inhibitors useful as antibacterial agents
CZ201126A3 (cs) * 2011-01-18 2012-05-09 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Zpusob výroby substituovaných diamidu fosfonových kyselin
EP3578563B1 (en) * 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors

Also Published As

Publication number Publication date
US9593137B2 (en) 2017-03-14
US10035814B2 (en) 2018-07-31
EP2794624A1 (en) 2014-10-29
JP2017081961A (ja) 2017-05-18
US20190106447A1 (en) 2019-04-11
EP3578563A1 (en) 2019-12-11
US20200283461A1 (en) 2020-09-10
JP6113185B2 (ja) 2017-04-12
DK3578563T3 (da) 2021-05-31
DK2794624T3 (da) 2019-07-22
EP2794624A4 (en) 2015-04-29
ES2874774T3 (es) 2021-11-05
WO2013095684A1 (en) 2013-06-27
US20150299232A1 (en) 2015-10-22
US12398162B2 (en) 2025-08-26
US20170233419A1 (en) 2017-08-17
HK1205515A1 (en) 2015-12-18
ES2734495T3 (es) 2019-12-10
CA2857490A1 (en) 2013-06-27
EP2794624B1 (en) 2019-05-15
US11279720B2 (en) 2022-03-22
JP2015502979A (ja) 2015-01-29
US20220306660A1 (en) 2022-09-29
US10562926B2 (en) 2020-02-18
EP3578563B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US12398162B2 (en) Guanine analogs as telomerase substrates and telomere length affectors
US20220306652A1 (en) Macrocyclic compounds for treating disease
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
ES2670601T9 (es) Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
HU228985B1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
CN108699046A (zh) 用ezh2抑制剂治疗成神经管细胞瘤的方法
ES2709003T3 (es) Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
EP3630080A1 (en) Use of ezh2 inhibitors for treating cancer
AU2020372832A1 (en) 4-Amino-imidazoquinoline compounds and use thereof
ES2580702B1 (es) Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
JP2019065054A (ja) オリゴヌクレオチドについてのホスホロジアミデート骨格結合
HK40018795A (en) Guanine analogs as telomerase substrates and telomere length affectors
HK40018795B (en) Guanine analogs as telomerase substrates and telomere length affectors
HK1205515B (en) Guanine analogs as telomerase substrates and telomere length affectors
ES2367968T3 (es) Sales de quino[4,3,2-kl]acridinio n8,n13-disustituidas utilizadas como agentes terapéuticos.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125